Maître de recherche FNRS
Professor Patrice D. Cani is leading a team at the Louvain Drug Research Institute (LDRI) of the University of Louvain (UCLouvain, Brussels, Belgium). He is researcher from the Belgian Fund for Scientific Research (FRS-FNRS) and WELBIO investigator.
After a B.Sc. degree in dietetics he joined the Faculty of Medicine of UCLouvain where he received a M.Sc. in Nutrition, another M.Sc. in Health Sciences, and a PhD in Biomedical Sciences (physiology and metabolism).
He is recipient of prestigious grants such as two ERC grants (Starting Grant ENIGMO 2013, PoC ERC grant Microbes4U 2016). He received the prize “Baillet Latour Grant for Medical Research” (2015), the “International Prize of Physiology Lucien Dautrebande” (2016). He has been elevated at the rank of Officer of the Walloon Merit (O.M.W.) and elected as associate member of the Royal Academy of Medicine of Belgium in 2016. He also received the Bauchau Chair at UNamur (2016) and the Francqui Chair at ULiège (2017).
In 2007, he published the discovery of the concept of metabolic endotoxemia, and more recently, he discovered the beneficial role of the bacteria Akkermansia muciniphila on obesity and cardiometabolic risk factors. His main research interests are the investigation of interactions between gut microbes and host in the context of obesity, type 2 diabetes, cardiometabolic disorders and cancer.
He is author/co-author of more than 250 scientific research publications, reviews and book chapters and ranked in the top 1% world-class researcher selected for his exceptional research performance and citations in the world (source Clarivate), h-index 76 and cited more than 26 000 times (Scopus, September 2019).
His motto is : “In Gut We Trust”.
|2000||Licencié en sciences biomédicales (nutrition humaine)||Université catholique de Louvain|
|2005||Diplômé d'études approfondies en sciences de la santé||Université catholique de Louvain|
|2006||Docteur en sciences biomédicales||Université catholique de Louvain|
|1998||Graduat en Diététique||Institut Paul Lambin|
|Aspects moléculaires et cellulaires de la nutrition||WSBIM2181|
His main research interests are the investigation of interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes, cardiometabolic disorders and metabolic inflammation.
In 2007, he published the discovery of the concept of metabolic endotoxemia, and more recently, he discovered the beneficial role of the bacteria Akkermansia muciniphila on obesity and cardiometabolic risk factors (published in PNAS 2013 and Nature Medicine 2017). The first proof-of-concept human study with Akkermansia muciniphila is now available and published in Depommier et al Nature Medicine 2019.